<DOC>
	<DOCNO>NCT02400866</DOCNO>
	<brief_summary>This aim study evaluate safety efficacy olanzapine prevention chemotherapy-induced nausea vomit patient receive moderately emetogenic chemotherapy randomize , double-blind , placebo-controlled trial .</brief_summary>
	<brief_title>A Randomized Study Olanzapine Prevention CINV Patients Receiving Moderately Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Olanzapine</mesh_term>
	<criteria>19 year age history receive moderately highly emetogenic chemotherapy last 6 month , receive first course MEC include one follow agent : Carboplatin , Cyclophosphamide ≤ 1,500 mg/m2 , Daunorubicin , Doxorubicin &lt; 60 mg/m2 , Epirubicin ≤ 90 mg/m2 , Irinotecan , Oxaliplatin , Melphalan , Methotrexate ≥ 250 mg/m2 ECOG performance status 02 predict life expectancy ≥ 3 month adequate bone marrow , kidney , liver functionas evidence : ANC ≥ 1,500/mm3 , platelet count ≥ 100,000/mm3 , total bilirubine ≤ 2 x ULN , AST ≤ 3 x ULN , ALT ≤ 3 x ULN ( subject know liver metastasis , total bilirubin ≤ 3 x ULN , AST ≤ 5 x ULN , ALT ≤ 5 x ULN ) , Creatinine ≤ 1.5 x ULN Ccr ≥ 50 ml/min episode nausea vomit last 24 hour enrollment subject provide write informed consent Exclusion criterion : subject uncontrolled neuropsychiatric disease ( alcohol abuse , seizure , psychosis etc ) except malignant tumor subject schedule receive highly emetogenic chemotherapeutic agent : Doxorubicin Epirubicin + cyclophosphamide , Cisplatin ≥ 50 mg/m2 , Carmustine &gt; 250 mg/m2 , Cisplatin ≥ 50 mg/m2 , Cyclophosphamide &gt; 1,500 mg/m2 , Dacarbazine , Doxurubicine ≥ 60 mg/m2 , Epirubicine &gt; 90 mg/m2 , Ifosfamide ≥ 2 g/m2 per dose , Mechlorethamine , Streptozocin contraindication administration palonosetron , dexamethasone , olanzapine due hypersensitivity reason subject severe cognitive impairment subject symptomatic uncontrolled brain metastasis brain tumor female subject childbearing potential dose agree use proper contraceptive method limit breast feed subject take follow agent : risperidone , quetiapine , clozapine , phenothiazine , butyrophenone , 5HT3 antagonist , bezamides , domperidone , cannabinoids , NK1 antagonist , bezodiazepines subject plan receive chemotherapy , abdomial radiation , surgery , immunotherapy history arrhythmia , uncontrolled congestive heart failure , acute myocardial infarction durting last 6 month history uncontrolled diabetes subject use investigational drug within 30 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>cancer patient receive moderately emetogenic chemotherapy</keyword>
</DOC>